Time Management and increased Productivity . Visualize
[…]
Read More[…]
Read MoreFull audio lectures for receptors, neuro-transmitters and mechanism of action of different psychoactive drugs Definitions: Agonist, antagonist, partial agonist, partial antagonist Partial Agonist Inverse Agonist Antagonist: Alleusteric: Imagine if we have baseline
Read MoreDiagnosing bipolar disorder Many patients with borderline personality disorder or other forms of moodiness are wrongly diagnosed as having bipolar disorder. On the other hand, it is simultaneously true that many patients with bipolar disorder (especially bipolar II disorder) continue to be misdiagnosed as having a […]
Read MoreModafinil (US brand name Provigil® and generic) is a wakefulness promoting agent. Here is key information about this medication. FDA-approved indications To improve wakefulness in adult patients with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD) Dosage 1. Adults Narcolepsy or OSA: 200 mg […]
Read MoreTo screen for Obstructive Sleep Apnea, we need to check for multiple factors. The STOP-Bang questionnaire looks at these multiple factors. A link to information about the questionnaire is provided below. 1. Snoring Ask the patient and the person who sleeps […]
Read MoreThe FDA issued a warning on May 3, 2016 about aripiprazole stating that “compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported with the use of aripiprazole (Abilify®, Abilify Maintena®, Aristada®, and generics). These uncontrollable urges were reported to have […]
Read MoreOlanzapine (US brand name Zyprexa® and generic) is a second-generation (atypical) antipsychotic. Here is basic information about this medication. FDA-approved indications 1. As oral formulation for: a. Schizophrenia in adults and adolescents b. Manic or mixed episodes associated with bipolar I disorder in adults and adolescents […]
Read MorePaliperidone extended-release (US brand name Invega® and generic) is a second-generation (“atypical”) antipsychotic. FDA-approved indications 1. Treatment of schizophrenia in adults and adolescents (ages 12-17) 2. Treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. Dosage A. Schizophrenia […]
Read More